1-(溴甲基)-2-甲基萘 | 61172-29-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-(溴甲基)-2-甲基萘
• 英文名称: 1-bromomethyl-2-methylnaphthalene
• 英文别名: 1-(Bromomethyl)-2-methylnaphthalene
• CAS: 61172-29-0
• 化学式: C₁₂H₁₁Br
• 分子量: 235.123
• InChiKey: KHIPWBHOPWKEDV-UHFFFAOYSA-N

物化性质

• 沸点：
  328.1±11.0 °C(Predicted)
• 密度：
  1.388±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险品运输编号：
  3261
• 危险性描述：
  H314,H317

反应信息

• 作为反应物：
  描述：

  1-(溴甲基)-2-甲基萘 在 盐酸 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 萘甲羟胺
  参考文献：
  名称：

  45.氨基氧基衍生物。第二部分 N-羟基二胍的一些衍生物

  摘要：

  DOI：

  10.1039/jr9600000229
• 作为产物：
  描述：

  二甲基萘 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氯化碳 为溶剂， 以85%的产率得到1-(溴甲基)-2-甲基萘
  参考文献：
  名称：

  Synthesis of a novel series of topographically constrained amino acids: Benzo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids

  摘要：

  DOI：

  10.1016/0040-4039(95)00617-l

文献信息

• NaIO4–DMF: a novel reagent for the oxidation of organic halides to carbonyl compounds
  作者：Sasmita Das、A.K. Panigrahi、Golak C. Maikap

  DOI：10.1016/s0040-4039(02)02885-x

  日期：2003.2

  NaIO4–DMF oxidises various primary and secondary halides to the corresponding aldehydes and ketones under mild conditions (150°C/40–60 min) in high yields (70–90%).

  NaIO 4 –DMF在温和的条件下（150°C / 40–60分钟）将各种伯卤和仲卤化物氧化为相应的醛和酮，收率很高（70–90％）。
• Facile reductive coupling of benzylic halides with ferrous oxalate dihydrate
  作者：Jitender M. Khurana、Sushma Chauhan、Golak C. Maikap

  DOI：10.1039/b211792d

  日期：2003.5.15

  Facile reductive coupling of benzylic halides is reported with ferrous oxalate dihydrate in DMF or HMPA under nitrogen atmosphere at 155–160 °C. The coupling is proposed to proceed by two successive oxidative additions of benzylic halides to ferrous oxalate to give an intermediate organoiron complex which undergoes concerted dimerization to give the corresponding reductively coupled dimers in high yields.

  报道称，在氮气气氛下，使用二水合草酸亚铁在DMF或HMPA中，于155-160°C的温度下，可以轻松实现苄基卤化物的还原耦合反应。该耦合反应被认为是通过苄基卤化物对草酸亚铁的两次连续氧化加成，生成一种中间体有机铁配合物，该配合物随后经历协同二聚反应，以高产率得到相应的还原耦合二聚体。
• [EN] RENIN INHIBITORS<br/>[FR] INHIBITEURS DE RÉNINE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2011020193A1

  公开（公告）日：2011-02-24

  Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency. wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6-alkyl or C3-6-cycloalkyl, wherein said C1-6-alkyl or C3-6-cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or -(C=O)-, -CH(OH)-, -CH2- or =CH-; U is a bond or -CH2-, or for the case when V is =CH-, U is -CH=; X is =CH-, =CF-, =C(OR3)-, or -C=O-; and Y is =CH-, =CF-, =N-, or for the case when X is -C=O-, Y is -N(R3)-.

  肾素抑制剂是螺环哌啶酰胺，其结构式为（I），以及其药物组合物，用于治疗心血管疾病和肾功能不全。其中n在每次出现时，独立地为0、1或2；R1为氢、C1-6-烷基或C3-6-环烷基，其中所述的C1-6-烷基或C3-6-环烷基基团可以独立地被1-3个卤素取代；A为（i）五元或六元饱和或不饱和杂环或碳环单环，或（ii）与另一个五元或六元饱和或不饱和杂环或碳环单环融合的五元或六元饱和或不饱和杂环或碳环环；V为键或-(C=O)-、-CH(OH)-、-CH2-或=CH-；U为键或-CH2-，或当V为=CH-时，U为-CH=；X为=CH-、=CF-、=C(OR3)-或-C=O-；Y为=CH-、=CF-、=N-，或当X为-C=O-时，Y为-N(R3)-。
• [EN] HALOALUMINOXANE COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSIS<br/>[FR] COMPOSITIONS D'HALOALUMINOXANE, PREPARATION ET UTILISATION DE CELLES-CI DANS DES CATALYSES
  申请人：ALBEMARLE CORP

  公开号：WO2005066191A1

  公开（公告）日：2005-07-21

  Novel haloaluminoxane compositions have been formed. The halogen is fluorine, chlorine, and/or bromine, and the amount of halogen atoms present in said composition is in the range of about 0.5 mole % to about 15 mole % relative to aluminum atoms.

  已经形成了新的氧化铝卤代铝簇合物。卤素可以是氟、氯和/或溴，而该簇合物中存在的卤素原子的数量在相对于铝原子约0.5摩尔％至约15摩尔％的范围内。
• Methods for treating CNS disorders with 4-imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197622A1

  公开（公告）日：2007-08-23

  The present invention relates to methods for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, Ar, R 1 , R 1′ , R 2 , and n are as defined in the specification and to their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神疾病，如精神分裂症、神经疾病，如帕金森病、神经退行性疾病，如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病，如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收的障碍、体温稳态的障碍和功能障碍、睡眠和昼夜节律的障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中化合物I的R、Ar、R1、R1'、R2和n如规范中所定义，并且包括它们的药物活性盐、外消旋混合物、对映异构体和互变异构体。本发明还涉及化合物I的新型化合物、含有它们的组合物以及它们的制备方法。